NCT04375709

Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);

Status unknown Last updated 12 May 2020

What this trial tests

trial testing Physical exercise in Covid-19 (New Coronavirus) Infection in 60 participants. Status unknown.

Timeline

15 March 2020

Primary endpoint
30 June 2021

31 August 2021

Quick facts

Lead sponsor	Kantonsspital Winterthur KSW
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	15 March 2020
Primary completion	30 June 2021
Estimated completion	31 August 2021
Sites	1 location across Switzerland

Drugs / interventions tested

• Physical exercise
• Education sessions

Conditions studied

• Covid-19 (New Coronavirus) Infection — all drugs for Covid-19 (New Coronavirus) Infection →

Sponsor

Kantonsspital Winterthur KSW — full company profile →

Who can join

18 and older, any sex, with Covid-19 (New Coronavirus) Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to observe the long-term health-related quality of life (HRQOL) and physical performance in individuals hospitalized due to a COVID-19 infection. Therefore, data is extracted from a study-site standard aftercare program which has been adjusted for this patient population. This comprehensive aftercare program includes education sessions and physical exercise. A second aim is to observe adherence and feasibility to the program and if indicated compare the clinical data and outcomes from patients following the program with patients denying to participate in guided exercise and education sessions.

It is expected that patients hospitalized due to COVID-19 infection show a reduction in physical performance and HRQOL directly after discharge. The severity of illness is hypothesized to be associated with a reduction as well in HRQOL and physical performance after one-year post-discharge.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. COVID-19: Characteristics and Therapeutics.
   Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
2. Quality of life of COVID-19 critically ill survivors after ICU discharge: 90 days follow-up.
   Gamberini L, Mazzoli CA, Sintonen H, Colombo D, et al · · 2021 · cited 47× · PMID 33977415 · DOI 10.1007/s11136-021-02865-7
3. Feasibility of an Outpatient Training Program after COVID-19.
   Betschart M, Rezek S, Unger I, Beyer S, et al · · 2021 · cited 19× · PMID 33918887 · DOI 10.3390/ijerph18083978